Progress in the treatment of type 1 diabetes mellitus

HOME PAGE    合作伙伴    Progress in the treatment of type 1 diabetes mellitus

The basic research on diabetes in China has made remarkable progress. Scientists from the Department of Endocrinology, Huashan Hospital Affiliated to Fudan University have found that gamma-aminobutyric acid can prevent and reverse type 1 diabetes in mice. Recent studies have found that gamma-aminobutyric acid can also play a role in human islet cells. The results were recently published in the International Diabetes Authoritative Academic Journal Diabetes.

Type 1 diabetes is common in children and adolescents with unclear etiology. At present, type 1 diabetes mellitus can not be cured, patients only have long-term insulin injection to control symptoms.

Under the leadership of Dr. Wang Qinghua, Professor of Fudan University and Scholar of National Thousand-Person Program, and several experts from the Department of Endocrinology of Huashan Hospital and University of Toronto, Canada, we studied diabetes mellitus by transplanting human islets into immunodeficient diabetic mice. It was found that gamma-aminobutyric acid therapy could promote the proliferation of transplanted human islet beta cells, increase insulin level and increase insulin level. The findings suggest that gamma-aminobutyric acid is feasible in the treatment of type 1 diabetes mellitus.

The Department of Endocrinology of Huashan Hospital, funded by the American Adolescent Diabetes Foundation, has completed a phase 1 clinical trial of gamma-aminobutyric acid in healthy volunteers and obtained key pharmacokinetic data of gamma-aminobutyric acid. At present, the team is preparing a phase 2 clinical trial of gamma-aminobutyric acid in newly diagnosed type 1 diabetic patients. In particular, team experts pointed out that only randomized, double-blind and controlled clinical studies in patients with type 1 diabetes can ultimately prove that gamma-aminobutyric acid can effectively treat type 1 diabetes.